Literature DB >> 8264622

Functional evidence for a second tumor suppressor gene on human chromosome 17.

P Chen1, N Ellmore, B E Weissman.   

Abstract

The development and progression of human tumors often involves inactivation of tumor suppressor gene function. Observations that specific chromosome deletions correlate with distinct groups of cancer suggest that some types of tumors may share common defective tumor suppressor genes. In support of this notion, our initial studies showed that four human carcinoma cell lines belong to the same complementation group for tumorigenic potential. In this investigation, we have extended these studies to six human soft tissue sarcoma cell lines. Our data showed that hybrid cells between a peripheral neuroepithelioma (PNET) cell line and normal human fibroblasts or HeLa cells were nontumorigenic. However, hybrid cells between the PNET cell line and five other soft tissue sarcoma cell lines remained highly tumorigenic, suggesting at least one common genetic defect in the control of tumorigenic potential in these cells. To determine the location of this common tumor suppressor gene, we examined biochemical and molecular polymorphic markers in matched pairs of tumorigenic and nontumorigenic hybrid cells between the PNET cell line and a normal human fibroblast. The data showed that loss of the fibroblast-derived chromosome 17 correlated with the conversion from nontumorigenic to tumorigenic cells. Transfer of two different chromosome 17s containing a mutant form of the p53 gene into the PNET cell line caused suppression of tumorigenic potential, implying the presence of a second tumor suppressor gene on chromosome 17.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8264622      PMCID: PMC358403          DOI: 10.1128/mcb.14.1.534-542.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

1.  Selective transfer of individual human chromosomes to recipient cells.

Authors:  P J Saxon; E S Srivatsan; G V Leipzig; J H Sameshima; E J Stanbridge
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

2.  Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids.

Authors:  E S Srivatsan; W F Benedict; E J Stanbridge
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

3.  Tumorigenicity of human HT1080 fibrosarcoma X normal fibroblast hybrids: chromosome dosage dependency.

Authors:  W F Benedict; B E Weissman; C Mark; E J Stanbridge
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

4.  Characterization of ouabain resistant, hypoxanthine phosphoribosyl transferase deficient human cells and their usefulness as a general method for the production of human cell hybrids.

Authors:  B Weissman; E J Stanbridge
Journal:  Cytogenet Cell Genet       Date:  1980

5.  Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids.

Authors:  E J Stanbridge; R R Flandermeyer; D W Daniels; W A Nelson-Rees
Journal:  Somatic Cell Genet       Date:  1981-11

6.  Chromosomal aberrations in human neuroblastomas.

Authors:  G M Brodeur; G Sekhon; M N Goldstein
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

7.  Suppression of malignancy in human cells.

Authors:  E J Stanbridge
Journal:  Nature       Date:  1976-03-04       Impact factor: 49.962

8.  Complementation of the tumorigenic phenotype in human cell hybrids.

Authors:  B E Weissman; E J Stanbridge
Journal:  J Natl Cancer Inst       Date:  1983-04       Impact factor: 13.506

9.  Mycoplasma detection-an obligation to scientific accuracy.

Authors:  E J Stanbridge
Journal:  Isr J Med Sci       Date:  1981-07

10.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

View more
  6 in total

1.  Tumor cell complementation groups based on myogenic potential: evidence for inactivation of loci required for basic helix-loop-helix protein activity.

Authors:  A N Gerber; S J Tapscott
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

2.  Assignment of three loci: tumor suppressor protein-53 (TP53), retinoic acid receptor A (RARA), collagen 1A1 (COL1A1) to Syrian hamster chromosome 9. Evidence that this chromosome is homologous with human chromosome 17, mouse chromosome 11, and rat chromosome 10.

Authors:  M Q Islam; G Fång; K Islam; G Levan
Journal:  Mamm Genome       Date:  1995-12       Impact factor: 2.957

Review 3.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

4.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

5.  Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.

Authors:  M Ittmann; R Wieczorek; P Heller; A Dave; J Provet; J Krolewski
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

6.  Deletion mapping on chromosome 17p in medulloblastoma.

Authors:  E Steichen-Gersdorf; M Baumgartner; A Kreczy; H Maier; F M Fink
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.